BioBiz Buzz
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
BioBiz Buzz
25. Europe Doesn’t Need Boston Anymore: Inside Gilead’s $5B Tubulis Bet
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
For years, the narrative was simple: if you wanted a multibillion-dollar biotech outcome, you built in Boston or the Bay Area. Gilead’s up to $5 billion acquisition of Munich-based Tubulis just blew that up.
In this episode, Mike Ward and Andera Partners’ Sofia Ioannidou go inside one of Europe’s most important biotech exits to unpack what really drove the deal, and why it wasn’t just about a single ADC asset, but a platform Gilead believes can keep delivering. They dig into the mechanics behind getting “transaction-ready,” the discipline required to turn early clinical data into strategic leverage, and why most companies won’t, and shouldn’t, command Tubulis-level valuations.
Plus: what this means for Munich as an emerging ADC hub, how investors are recalibrating expectations in a tougher funding market, and the uncomfortable truth for founders chasing billion-dollar exits.
If you still think geography determines outcome in biotech, this conversation will challenge that assumption.
● Feedback
● Subscribe (Get notified when new episodes are available. NO marketing!)